A Lifetime of Prevention
2002; Lippincott Williams & Wilkins; Volume: 106; Issue: 24 Linguagem: Inglês
10.1161/01.cir.0000046804.13847.5d
ISSN1524-4539
Autores Tópico(s)Cardiac pacing and defibrillation studies
ResumoHomeCirculationVol. 106, No. 24A Lifetime of Prevention Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBA Lifetime of PreventionThe Case of Heart Failure Salim Yusuf, DPhil, FRCPC and Bertram Pitt, MD Salim YusufSalim Yusuf From McMaster University (S.Y.), Hamilton, Ontario, Canada, and the University of Michigan, Ann Arbor (B.P.). and Bertram PittBertram Pitt From McMaster University (S.Y.), Hamilton, Ontario, Canada, and the University of Michigan, Ann Arbor (B.P.). Originally published10 Dec 2002https://doi.org/10.1161/01.CIR.0000046804.13847.5DCirculation. 2002;106:2997–2998It is widely acknowledged that heart failure (HF) is a growing public health and clinical problem and that, once diagnosed, the prognosis is grim. In this issue of Circulation, Lloyd-Jones and colleagues1 provide a lifetime perspective of HF from the Framingham Heart Study. Several messages are notable. First, the lifetime risk of developing HF at all ages is ≈20 percent in both men and women. This contrasts with the fact that short-term risks are substantially lower in younger individuals compared with older individuals (eg, 0.5% 5-year risk versus 21.0% lifelong risk, or a 40-fold difference in those 40 years of age; 1% versus 20%, or a 20-fold difference in those 60 years of age; and 8% versus 20%, or a 2.5-fold difference in those 80 years of age). This implies that for preventive strategies to be fully effective against HF, they may have to be implemented throughout the lifetime of an individual.See p 3068Second, the analysis by Lloyd-Jones et al confirms the importance of hypertension and myocardial infarction, which together account for about three quarters of the population-attributable risk of HF. Both myocardial infarction2 and hypertension3 are largely preventable with currently known and available strategies (Table). The importance of hypertension is exemplified by the 2-fold increase in risk of HF among those with systolic blood pressure (BP) >160 and diastolic BP >90 mm Hg compared with those with both systolic BP <140 and diastolic BP <90. This risk is likely to be continuous so that even lower rates of HF can be expected among those with systolic BP 40 Years of Age AffectedType of InterventionPopulation- Level Impact(A) Class IV HF + low ejection fraction<0.2Transplantation; left ventricular assist device, implantable cardiac defibrillatorTiny(B) Any congestive HF<2ACE inhibitors, β-blockers, spironolactoneModest(C) High-risk individuals (eg, those with hypertension or who have had a myocardial infarction) 25), plus those in above category>40Weight loss, plus above measuresLargeThe second major antecedent cause of HF is myocardial infarction. The risk of myocardial infarction can be reduced by avoidance of smoking and modification of the classical risk factors (eg, lowering LDL cholesterol, lowering BP). These risk factors can be favorably altered through population-level lifestyle changes, such as weight reduction, and through strong antitobacco campaigns and legislation. The importance of obesity in causing HF has recently been emphasized by a separate report from the Framingham Heart Study.4 In this regard, obesity should be considered a proximate risk factor for HF and may exert its influence both directly and indirectly, by promoting high BP, diabetes, dyslipidemia, and atherosclerosis. Therefore, primordial prevention efforts (ie, prevention of the development of risk factors through avoidance of obesity) are likely to have an impact on a number of manifestations of cardiovascular disease, including HF.To be successful in primordial prevention, a broad-ranging effort is needed, including urban planning, changing the nature of most kinds of work to promote physical activity, legislation that promotes consumption of healthy foods and discourages consumption of unhealthy foods (through positive and negative financial incentives), and education about healthy lifestyles throughout life. A multitiered approach at societal, community, and family levels, complemented by aggressive control of risk factors in high-risk individuals, is likely to yield the greatest impact.Thus far, research aimed at preventing HF in high-risk individuals has been relatively modest in comparison with the extensive efforts at discovering new treatments for patients after HF has developed. Apart from the BP-lowering trials3 and the Prevention trial of the Study of Left Ventricular Dysfunction (SOLVD), which used ACE inhibitors in those with low ejection fractions,5 there have been no other efforts that have primarily targeted the prevention of HF. By contrast, studies involving treatment of patients with clinical HF are numerous.6 These worthwhile efforts have established the roles of ACE inhibitors,7 β-blockers,8 and spironolactone9 in reducing mortality and morbidity and that of digoxin in preventing worsening HF, but further progress has been slow. Several years of treatment with all of these drugs could potentially prolong average survival by ≈3 to 4 years in HF patients (extrapolating from the SOLVD 12-year experience).10 At least a similar improvement in survival should be expected from preventive efforts (such as reduced obesity, BP lowering) in high-risk patients. However, because preventive efforts are likely to be applicable to much larger numbers of individuals, such efforts could lead to greater population-level benefits. At the other extreme, it is likely that an average survival extension of only a few months can be achieved by devices (eg, implantable cardiac defibrillator11 or left ventricular assist devices12), and more significant improvements can be achieved in highly selected individuals who undergo heart transplantation. Although these efforts certainly benefit very ill patients, the population-level impact is likely to be extremely small because it can only be applied to a very small group of patients.It is therefore important that we develop a population-level strategy of prevention of HF that applies to the large number of "at-risk" individuals. Such a strategy would complement our current approaches that are aimed at intensive management of patients with manifest HF. Implementation of our current knowledge of both prevention and treatment of hypertension, obesity, and atherosclerotic vascular disease has the potential to have a large impact on the age-specific incidence and mortality from HF.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Dr Salim Yusuf, DPhil, FRCPC, Population Health Research Institute, 2nd Floor, McMaster Clinic, Rm 252, 237 Barton St East, Hamilton, Ontario, Canada L8L 2X2. E-mail [email protected] References 1 Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002; 106: 3068–3072.LinkGoogle Scholar2 Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002; 360: 2–3.CrossrefMedlineGoogle Scholar3 Furberg CD, Psaty BM. Blood pressure and cardiovascular disease. In: Yusuf S, Cairns JA, Camm AJ, et al, eds. Evidence-Based Cardiology. 2nd ed. London, UK: BMJ Books; 2002. In press.Google Scholar4 Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. New Engl J Med. 2002; 347: 305–313.CrossrefMedlineGoogle Scholar5 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med. 1991; 325: 293–302.CrossrefMedlineGoogle Scholar6 Anderson B, Swedberg K. Management of overt heart failure. In: Yusuf S, Cairns JA, Camm AJ, et al, eds. Evidence-Based Cardiology. 2nd ed. London, UK: BMJ Books; 2002. In press.Google Scholar7 Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000; 355: 1575–1581.CrossrefMedlineGoogle Scholar8 Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA. 2000; 283: 1295–1302.CrossrefMedlineGoogle Scholar9 Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med. 1999; 341: 709–717.CrossrefMedlineGoogle Scholar10 Jong P, Yusuf S, Rousseau MF, et al. Enalapril improves survival and life expectancy in patients with reduced left ventricular ejection fractions. Available at: http://www.escardio.org/congress/berlin02/hotlines/Wednesday/XSOLVD_final.pdf. Accessed November 1, 2002.Google Scholar11 Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials: AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000; 21: 2071–2078.CrossrefMedlineGoogle Scholar12 Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. New Engl J Med. 2001; 345: 1435–1443.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Bergsten T, Nicholson A, Donnino R, Wang B, Fang Y and Natarajan S (2020) Predicting adults likely to develop heart failure using readily available clinical information, Preventive Medicine, 10.1016/j.ypmed.2019.105878, 130, (105878), Online publication date: 1-Jan-2020. O.S. S, G. V, A.R. M, N. R, S. H and A.N. K (2018) Long-term outcomes of patients admitted with heart failure in a tertiary care center in India, Indian Heart Journal, 10.1016/j.ihj.2018.01.016, 70, (S85-S89), Online publication date: 1-Jul-2018. Jiang X, Liu Y, Liu X, Wang W, Wang Z, Hu Y, Zhang Y, Zhang Y, Jose P, Wei Q and Yang Z (2018) Over-expression of a cardiac-specific human dopamine D5 receptor mutation in mice causes a dilated cardiomyopathy through ROS over-generation by NADPH oxidase activation and Nrf2 degradation, Redox Biology, 10.1016/j.redox.2018.07.008, 19, (134-146), Online publication date: 1-Oct-2018. Korhonen P, Kautiainen H, Järvenpää S and Kantola I (2013) Target organ damage and cardiovascular risk factors among subjects with previously undiagnosed hypertension, European Journal of Preventive Cardiology, 10.1177/2047487312474530, 21:8, (980-988), Online publication date: 1-Aug-2014. Sá-Silva S, Yokoo E and Salles-Costa R (2013) Fatores demográficos e hábitos de vida relacionados com a inatividade física de lazer entre gêneros, Revista de Nutrição, 10.1590/S1415-52732013000600003, 26:6, (633-645), Online publication date: 1-Dec-2013. Ruilope L (2011) Current challenges in the clinical management of hypertension, Nature Reviews Cardiology, 10.1038/nrcardio.2011.157, 9:5, (267-275), Online publication date: 1-May-2012. Baliga R and Young J (2012) Reducing the Burden of Stage B Heart Failure and the Global Pandemic of Cardiovascular Disease: Time to Go to War with the "Barefoot" Troops!, Heart Failure Clinics, 10.1016/j.hfc.2012.02.001, 8:2, (ix-xiii), Online publication date: 1-Apr-2012. Rodríguez-Artalejo F, Graciani A, Guallar-Castillón P, León-Muñoz L, Zuluaga M, López-García E, Gutiérrez-Fisac J, Taboada J, Aguilera M, Regidor E, Villar-Álvarez F and Banegas J (2011) Rationale and Methods of the Study on Nutrition and Cardiovascular Risk in Spain (ENRICA), Revista Española de Cardiología (English Edition), 10.1016/j.rec.2011.05.023, 64:10, (876-882), Online publication date: 1-Oct-2011. Rodríguez-Artalejo F, Graciani A, Guallar-Castillón P, León-Muñoz L, Zuluaga M, López-García E, Gutiérrez-Fisac J, Taboada J, Aguilera M, Regidor E, Villar-Álvarez F and Banegas J (2011) Justificación y métodos del estudio sobre nutrición y riesgo cardiovascular en España (ENRICA), Revista Española de Cardiología, 10.1016/j.recesp.2011.05.019, 64:10, (876-882), Online publication date: 1-Oct-2011. Cleland J, Coletta A, Witte K and Clark A (2009) Heart failure Men's Health, Third Edition, 10.3109/9781439808078-14, (120-152), Online publication date: 29-Jan-2009. Esmore D, Kaye D, Spratt P, Larbalestier R, Ruygrok P, Tsui S, Meyers D, Fiane A and Woodard J (2008) A Prospective, Multicenter Trial of the VentrAssist Left Ventricular Assist Device for Bridge to Transplant: Safety and Efficacy, The Journal of Heart and Lung Transplantation, 10.1016/j.healun.2008.02.012, 27:6, (579-588), Online publication date: 1-Jun-2008. Esmore D, Kaye D, Salamonsen R, Buckland M, Begg J, Negri J, Ayre P, Woodard J and Rosenfeldt F (2008) Initial Clinical Experience With the VentrAssist Left Ventricular Assist Device: The Pilot Trial, The Journal of Heart and Lung Transplantation, 10.1016/j.healun.2008.02.003, 27:5, (479-485), Online publication date: 1-May-2008. Esmore D, Spratt P, Larbalestier R, Tsui S, Fiane A, Ruygrok P, Meyers D and Woodard J (2007) VentrAssist™ left ventricular assist device: clinical trial results and Clinical Development Plan update, European Journal of Cardio-Thoracic Surgery, 10.1016/j.ejcts.2007.07.028, 32:5, (735-744), Online publication date: 1-Nov-2007. Young J and Narula J (2007) Preface, Cardiology Clinics, 10.1016/j.ccl.2007.10.002, 25:4, (xi-xiii), Online publication date: 1-Nov-2007. Gulliver G and Sweitzer N (2007) Risk Factor Management and Lifestyle Modification in Heart Failure Cardiovascular Therapeutics, 10.1016/B978-1-4160-3358-5.50019-X, (315-330), . Campbell D, Woodward M, Chalmers J, Colman S, Jenkins A, Kemp B, Neal B, Patel A and MacMahon S (2004) Prediction of Heart Failure by Amino Terminal-pro–B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease, Hypertension, 45:1, (69-74), Online publication date: 1-Jan-2005. Masi A, Aldag J and Jacobs J (2005) Rheumatoid Arthritis: Neuroendocrine Immune Integrated Physiopathogenetic Perspectives and Therapy, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2004.09.006, 31:1, (131-160), Online publication date: 1-Feb-2005. Laufs U, Herrmann W, Strehlow K, Nickenig G, Kindermann M, Böhm M, Scheller B, Nickl W, Müller P, Seeland U, Jung J, Fries R, Waßmann S, Scheffler P, Wilkens H, Wendler O, Schäfers H, Baumhäkel M, Cremers B, Link A and Hammer B (2004) Herz, Gefäße, Lunge Männersprechstunde, 10.1007/978-3-642-18705-6_3, (81-196), . Langheier J and Snyderman R (2004) Prospective medicine: the role for genomics in personalized health planning, Pharmacogenomics, 10.1517/phgs.5.1.1.25685, 5:1, (1-8), Online publication date: 1-Jan-2004. Desai S and Jessup M (2004) Epilogue, Medical Clinics of North America, 10.1016/j.mcna.2004.04.017, 88:5, (1369-1380), Online publication date: 1-Sep-2004. Campbell D (2003) Heart failure: how can we prevent the epidemic?, Medical Journal of Australia, 10.5694/j.1326-5377.2003.tb05620.x, 179:8, (422-425), Online publication date: 1-Oct-2003. Tang W and Francis G (2005) Novel pharmacological treatments for heart failure, Expert Opinion on Investigational Drugs, 10.1517/13543784.12.11.1791, 12:11, (1791-1801), Online publication date: 1-Nov-2003. Campbell D (2003) How should I combine β-blockers, ACE inhibitors and ARBs in the management of heart failure?, ACC Current Journal Review, 10.1016/S1062-1458(03)00226-5, 12:3, (55-58), Online publication date: 1-May-2003. Snyderman R and Sanders Williams R (2003) Prospective Medicine: The Next Health Care Transformation, Academic Medicine, 10.1097/00001888-200311000-00002, 78:11, (1079-1084), Online publication date: 1-Nov-2003. December 10, 2002Vol 106, Issue 24 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000046804.13847.5DPMID: 12473540 Originally publishedDecember 10, 2002 Keywordsheart failureEditorialsrisk factorspreventionPDF download Advertisement
Referência(s)